PolyNovo’s focus over the next twelve months will be to…
advance our Bone Void Filler agreement with Smith & Nephew towards a commercial application.
Annual Report 2016
Whilst PolyNovo has an agreement with Smith & Nephew for the use of the bone void filler in orthopaedic applications, this has not progressed in the past year. Smith & Nephew remains interested in developing the product within the orthopaedic applications and PolyNovo will pursue advancement of this licence.
Annual Report, 2017
PolyNovo has a licence agreement with Smith & Nephew for the use of NovoSorb two-part polymer for bone void filler in orthopaedic applications. Smith & Nephew have not progressed this product through the commercial phase and we will review the status of this agreement in due course.
Annual Report, 2018
PolyNovo has a licence agreement with Smith & Nephew for the use of NovoSorb two-part polymer for bone void filler in orthopaedic applications. Smith & Nephew have not progressed this product through the commercial phase and we will review the status of this agreement in due course.
It’s an unfortunately all-too-familiar story when very small companies deal with very big companies.
S & N’s loss, I say.
PNV Price at posting:
60.5¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)